FBR Capital Markets Comments on Shire PLC Following Announcement of ViroPharma Acquisition

In a report published Tuesday, FBR Capital Markets analyst William Tanner commented on recent developments related to

. In the report, FBR Capital Markets noted, “The announcement that Shire plans to acquire ViroPharma probably comes as little surprise to many investors, given expectations over the past few months that such a move might occur. We view the acquisition, particularly Cinryze, as a logical complement to Shire's Orphan disease business, in general, and a focus on HAE, specifically. In addition to the restructuring activity, we expect Shire to continue to seek new commercial opportunities, as well as to divest business lines that may no longer be viewed as core or that are underperforming.” Shire PLC closed on Monday at $135.33.